#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Dermatitis atopic Dementia Alzheimer's type Asthma Breast cancer metastatic Type 2 diabetes mellitus Non-small cell lung cancer metastatic More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Mantle cell lymphoma refractory Henoch-Schonlein purpura Gastrointestinal cancer metastatic Pleural mesothelioma Endocrine ophthalmopathy Pouchitis Juvenile psoriatic arthritis Pulmonary alveolar haemorrhage Lymphoma Fontan procedure Pulmonary sarcoidosis Hodgkin's disease Ovarian epithelial cancer Cluster headache Autologous haematopoietic stem cell transplant More trials…

    Learn about Rare Diseases

    Shprintzen-Goldberg syndrome Mucous membrane pemphigoid – Trials in Disease Lennox-Gastaut syndrome – Basic Information Medulloblastoma recurrent – Treatment Bronchopulmonary dysplasia Alternating hemiplegia of childhood – Life with Disease Hepatic angiosarcoma – Life with Disease Carcinoid syndrome – Diagnostics Metachromatic leukodystrophy – Diagnostics Mantle cell lymphoma – Diagnostics More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Cetirizine Dihydrochloride Trametinib Dimethyl Sulfoxide Valproate Semisodium Lebrikizumab Pemigatinib Hct116-B Sugammadex Mepacrine BENZYLPENICILLIN POTASSIUM Danicopan Doconexent Peboctocogene Camaparvovec Bay 3018250 Clopidogrel Hydrogen Sulfate Colistin Sulfate Lenalidomide Remimazolam Fluoroethyltyrosine F-18 Dronedarone Follitropin Beta More therapies…

    Learn about Your Condition

    Tricuspid valve disease Clostridium difficile colitis Psychotic disorder Coma Paedophilia Tubulointerstitial nephritis Pneumococcal infection Hairy cell leukaemia Urticaria cholinergic Cardiac disorder Pseudomyxoma peritonei Renal injury Angiopathy Torticollis Fatty acid oxidation disorder More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Institut Regional Du Cancer De Montpellier

Institut Regional Du Cancer De Montpellier

208 Avenue Des Apothicaires, Montpellier, 34298, France

Want to learn more about this study or check if you can participate? Contact us.

  • A study comparing Rinatabart Sesutecan to other treatments in patients with endometrial cancer who have previously received platinum-based chemotherapy and PD-L1 therapy

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Endometrial cancer recurrent
    • Endometrial cancer metastatic
    • Endometrial cancer
    Investigated Drugs:
    • HUMAN IGG1 KAPPA MONOCLONAL ANTIBODY AGAINST FOLR1 CONJUGATED TO 1-[(2R,3R,4R,5S,52S)-1,2,3,4,5-PENTAHYDROXY-52-{[(2S)-1-{[(2S)-5-CARBAMOYLAMINO-1-OXO-1-{3-[({[(1S,9S)-9-ETHYL-5-FLUORO-9-HYDROXY-4-METHYL10,13-DIOXO-2,3,9,10,13,15-HEXAHYDRO-1H,12HBENZO[DE]PYRANO[3′,4′:6,7]INDOLIZINO[1,2-B]QUINOLIN-1-YL]CARBAMOYL}OXY)METHYL]ANILINO}PENTAN-2-YL]AMINO}-3-METHYL-1-OXOBUTAN-2-YL]CARBAMOYL}-7-[(2S,3R,4R,5R)-2,3,4,5,6-PENTAHYDROXYHEXYL]-46,54-DIOXO10,13,16,19,22,25,28,31,34,37,40,43-DODECAOXA-7,47,53-TRIAZANONAPENTACONTAN-59-YL]-2,5-DIOXOPYRROLIDIN-3-YL
    • Doxorubicin Hydrochloride
    • Paclitaxel
    Belgium Denmark Finland France Germany Greece +5

  • Study of inavolisib, ribociclib, and fulvestrant for patients with advanced hormone-receptor-positive, HER2-negative breast cancer.

    Recruiting

    2 1 1
    Investigated Diseases:
    • Breast cancer
    Investigated Drugs:
    • Fulvestrant
    • Inavolisib
    • Ribociclib
    France Germany Italy Poland Spain

  • Study of Sotorasib, Panitumumab and a drug combination for patients with metastatic colorectal cancer with KRAS p.G12C mutation.

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Colorectal cancer metastatic
    Investigated Drugs:
    • Sotorasib
    • Panitumumab
    • Irinotecan Hydrochloride Trihydrate
    Austria Belgium Bulgaria Czechia Denmark Estonia +12

  • Study comparing datopotamab deruxtecan with or without durvalumab to chemotherapy with pembrolizumab for patients with triple-negative breast cancer

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Triple negative breast cancer
    Investigated Drugs:
    • Carboplatin
    • Datopotamab Deruxtecan
    • Durvalumab
    France Italy Poland Spain

  • Study of ivonescimab alone or with ligufalimab versus pembrolizumab for patients with recurrent or metastatic head and neck squamous cell cancer

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Squamous cell carcinoma of head and neck
    Investigated Drugs:
    • LIGUFALIMAB
    • Ivonescimab
    • Pembrolizumab
    Belgium France Spain

  • A Study of Ivonescimab Combined with Fluorouracil, Folinic Acid, and Oxaliplatin Compared to Bevacizumab for Patients with Metastatic Colorectal Cancer

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Colorectal cancer metastatic
    Investigated Drugs:
    • Ivonescimab
    • Bevacizumab
    • Fluorouracil
    Belgium Czechia France Germany Hungary Italy +2

  • A Study of BMS-986504 Combined with Nab-Paclitaxel and Gemcitabine for Patients with Untreated Metastatic Pancreatic Cancer with MTAP Gene Deletion

    Recruiting

    4 1 1
    Investigated Drugs:
    • 2-[4-[4-(AMINOMETHYL)-1-OXO-2H-PHTHALAZIN-6-YL]-2-METHYLPYRAZOL-3-YL]-4-CHLORO-6-CYCLOPROPYLOXY-3-FLUOROBENZONITRILE
    • Gemcitabine
    • Paclitaxel Albumin-Bound
    Austria Belgium Czechia Denmark France Germany +9

  • A Study of Zanidatamab for Patients with Previously Treated HER2-Expressing Solid Tumors

    Recruiting

    2 1 1
    Investigated Drugs:
    • Zanidatamab
    France Italy Spain

  • A study of saruparib with radiotherapy and hormone therapy for men with high-risk prostate cancer who have a BRCA gene mutation

    Recruiting

    3 1 1
    Investigated Diseases:
    • Prostate cancer
    Investigated Drugs:
    • Saruparib
    • Abiraterone Acetate
    Austria Belgium Finland France Germany Hungary +5

  • Testing sacituzumab govitecan and trastuzumab deruxtecan in alternating pattern for patients with HER2-low triple-negative breast cancer

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Triple negative breast cancer
    Investigated Drugs:
    • Sacituzumab Govitecan
    • Trastuzumab Deruxtecan
    France
Previous Page
1 2 3 4 … 25
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!